vs
Hippo Holdings Inc.（HIPO）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Hippo Holdings Inc.的1.7倍（$207.3M vs $120.4M），Hippo Holdings Inc.净利率更高（5.0% vs -62.0%，领先67.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 18.2%），Hippo Holdings Inc.自由现金流更多（$9.1M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 18.9%）
河马谷庄园是一座甘蔗种植园，坐落于津巴布韦东南部奇雷济区奇雷济镇附近，位于伦迪河沿岸，毗邻莫桑比克边境，是当地重要的蔗糖产业园区。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
HIPO vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $120.4M | $207.3M |
| 净利润 | $6.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 5.6% | -54.7% |
| 净利率 | 5.0% | -62.0% |
| 营收同比 | 18.2% | 25.9% |
| 净利润同比 | -86.4% | 3.5% |
| 每股收益（稀释后） | $0.31 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $120.4M | $207.3M | ||
| Q3 25 | $120.6M | $159.9M | ||
| Q2 25 | $117.3M | $166.5M | ||
| Q1 25 | $110.3M | $139.3M | ||
| Q4 24 | $101.9M | $164.6M | ||
| Q3 24 | $95.5M | $139.5M | ||
| Q2 24 | $89.6M | $147.0M | ||
| Q1 24 | $85.1M | $108.8M |
| Q4 25 | $6.0M | $-128.6M | ||
| Q3 25 | $98.1M | $-180.4M | ||
| Q2 25 | $1.3M | $-115.0M | ||
| Q1 25 | $-47.7M | $-151.1M | ||
| Q4 24 | $44.2M | $-133.2M | ||
| Q3 24 | $-8.5M | $-133.5M | ||
| Q2 24 | $-40.5M | $-131.6M | ||
| Q1 24 | $-35.7M | $-170.7M |
| Q4 25 | 5.6% | -54.7% | ||
| Q3 25 | 81.3% | -106.9% | ||
| Q2 25 | 3.4% | -64.8% | ||
| Q1 25 | -41.3% | -102.6% | ||
| Q4 24 | 46.3% | -74.3% | ||
| Q3 24 | -5.4% | -94.6% | ||
| Q2 24 | -40.7% | -79.1% | ||
| Q1 24 | -38.7% | -151.9% |
| Q4 25 | 5.0% | -62.0% | ||
| Q3 25 | 81.3% | -112.8% | ||
| Q2 25 | 1.1% | -69.0% | ||
| Q1 25 | -43.2% | -108.5% | ||
| Q4 24 | 43.4% | -80.9% | ||
| Q3 24 | -8.9% | -95.7% | ||
| Q2 24 | -45.2% | -89.5% | ||
| Q1 24 | -42.0% | -156.8% |
| Q4 25 | $0.31 | $-1.28 | ||
| Q3 25 | $3.77 | $-1.81 | ||
| Q2 25 | $0.05 | $-1.17 | ||
| Q1 25 | $-1.91 | $-1.57 | ||
| Q4 24 | $1.81 | $-1.34 | ||
| Q3 24 | $-0.34 | $-1.40 | ||
| Q2 24 | $-1.64 | $-1.52 | ||
| Q1 24 | $-1.47 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $218.3M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $436.1M | $-80.0M |
| 总资产 | $1.9B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $218.3M | $421.0M | ||
| Q3 25 | $247.7M | $202.5M | ||
| Q2 25 | $198.9M | $176.3M | ||
| Q1 25 | $140.9M | $127.1M | ||
| Q4 24 | $197.6M | $174.0M | ||
| Q3 24 | $191.2M | $150.6M | ||
| Q2 24 | $175.9M | $480.7M | ||
| Q1 24 | $223.4M | $112.3M |
| Q4 25 | $436.1M | $-80.0M | ||
| Q3 25 | $421.5M | $9.2M | ||
| Q2 25 | $332.5M | $151.3M | ||
| Q1 25 | $322.8M | $144.2M | ||
| Q4 24 | $362.1M | $255.0M | ||
| Q3 24 | $326.4M | $346.8M | ||
| Q2 24 | $322.6M | $432.4M | ||
| Q1 24 | $351.2M | $140.3M |
| Q4 25 | $1.9B | $1.5B | ||
| Q3 25 | $1.9B | $1.2B | ||
| Q2 25 | $1.7B | $1.3B | ||
| Q1 25 | $1.5B | $1.3B | ||
| Q4 24 | $1.5B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.5B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.2M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $9.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | 7.6% | -48.6% |
| 资本支出强度资本支出/营收 | 0.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.53× | — |
| 过去12个月自由现金流最近4个季度 | $14.8M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $9.2M | $-99.8M | ||
| Q3 25 | $16.9M | $-91.4M | ||
| Q2 25 | $24.7M | $-108.3M | ||
| Q1 25 | $-35.6M | $-166.5M | ||
| Q4 24 | $47.5M | $-79.3M | ||
| Q3 24 | $46.8M | $-67.0M | ||
| Q2 24 | $-10.6M | $-77.0M | ||
| Q1 24 | $17.7M | $-190.7M |
| Q4 25 | $9.1M | $-100.8M | ||
| Q3 25 | $16.8M | $-92.7M | ||
| Q2 25 | $24.6M | $-110.7M | ||
| Q1 25 | $-35.7M | $-167.8M | ||
| Q4 24 | $47.2M | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | $-10.7M | $-79.0M | ||
| Q1 24 | $17.6M | $-193.9M |
| Q4 25 | 7.6% | -48.6% | ||
| Q3 25 | 13.9% | -58.0% | ||
| Q2 25 | 21.0% | -66.5% | ||
| Q1 25 | -32.4% | -120.5% | ||
| Q4 24 | 46.3% | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | -11.9% | -53.7% | ||
| Q1 24 | 20.7% | -178.2% |
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 0.1% | 0.8% | ||
| Q2 25 | 0.1% | 1.5% | ||
| Q1 25 | 0.1% | 1.0% | ||
| Q4 24 | 0.3% | 0.1% | ||
| Q3 24 | 0.0% | 1.2% | ||
| Q2 24 | 0.1% | 1.4% | ||
| Q1 24 | 0.1% | 3.0% |
| Q4 25 | 1.53× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 19.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HIPO
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
